Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics; and head, Steinman Lab, Stanford Medicine
Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis - Recent Updates
June 9th 2023In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.
Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis: Recent Updates
May 31st 2023In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS. [LISTEN TIME: 48 minutes]
Amylyx’s New Treatment for the ALS Patient Community: Lawrence Steinman, MD
October 17th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses what Amylyx’s FDA approved therapy means for the patient community and future research that may be performed regarding the dosage of the treatment. [WATCH TIME: 5 minutes]
AMX0035’s Safety as a Treatment for Patients with ALS: Lawrence Steinman, MD
October 12th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses the biggest takeaway from the FDA approval of Amylyx’s therapy, marketed as Relyvrio, and the availability of the treatment for patients with ALS. [WATCH TIME: 5 minutes]
Approval of AMX0035 and the Future of Clinical Trials for ALS: Lawrence Steinman, MD
October 11th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discussed updates in ALS research along with the need in future studies following AMX005’s (Relyvrio; Amylyx Pharmaceuticals) recent FDA approval. [WATCH TIME: 4 minutes]
Breakthrough in ALS With FDA Approval of AMX0035: Lawrence Steinman, MD
October 10th 2022The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses Amylyx’s therapy that was recently approved by the FDA, and what it means for the ALS community and the global healthcare industry. [WATCH TIME: 5 minutes]
Epstein-Barr Virus and MS: Exploring Implications From Bench to Bedside
February 21st 2022Alberto Ascherio, MD, DrPH, and Lawrence Steinman, MD, join NeurologyLive in a conversation about the clinical and research implications of a causative relationship between Epstein-Barr virus and multiple sclerosis.
Advances in MS Treatment, ECTRIMS 2021 Takeaways: Lawrence Steinman, MD
October 20th 2021Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]
Impact of Ublituximab for Patients With Relapsing MS: Lawrence Steinman, MD
October 19th 2021The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University discussed the treatment’s potential in the multiple sclerosis space, where there are other competing drugs with similar safety profiles. [WATCH TIME: 4 minutes]
Expanded Data from ULTIMATE 1 and 2 Trials of Ublituximab: Lawrence Steinman, MD
October 15th 2021The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University spoke on the safety and efficacy of ublituximab in treating patients with relapsing forms of multiple sclerosis. [WATCH TIME: 4 minutes]